权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

KIR and HLA effects in CNS paraneoplastic syndromes and related neuroimmune conditions

KIR 和 HLA 对 CNS 副肿瘤综合征和相关神经免疫性疾病的影响

基本信息

批准号：
10266033
负责人：
Emmanuel J Mignot
金额：
$ 64.29万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10266033
关键词：
Affect Aftercare Age Age of Onset Alleles Antigens Area Autoantibodies Autoimmune B-Lymphocytes Brain CSF1 gene Cancer Patient Cells Cerebellar Ataxia Clinical Clinical Data Communicable Diseases Complement Complex Country DNA Data Data Set Databases Demyelinating Diseases Disease Encephalitis Exclusion Frequencies Functional disorder GEM gene Gene Dosage Gene Frequency Gene-Modified Genes Genetic Genetic Polymorphism Genotype Haplotypes Herpes encephalitis Heterogeneity Immune system Immunotherapy In Vitro LGI1 gene Lambert-Eaton Myasthenic Syndrome Ligands Limbic Encephalitis Literature Malignant Neoplasms Mediating Modeling Multiple Sclerosis Myasthenia Gravis Narcolepsy Natural Killer Cells Nature Nervous System Paraneoplastic Syndromes Neuraxis Neuroimmune Neurology Neuromyelitis Optica Nucleotides Outcome Ovarian Teratoma Paraneoplastic Syndromes Parkinson Disease Pathology Peripheral Nervous System Diseases Plasma Rare Diseases Reaction Reporting Research Research Personnel Resolution Role Sample Size Sampling Serum Severity of illness Signal Transduction Single Nucleotide Polymorphism Stiff-Person Syndrome Stratification Surface Surveys Symptoms T-Lymphocyte Techniques Testing Tissues Tumor Immunity Update Work amphiphysin base cancer immunotherapy case control dosage genome wide association study genome-wide genome-wide analysis neuroimmunology next generation sequencing novel prevent sample collection sex symptom cluster treatment response tumor

项目摘要

Abstract Novel neuroimmune disorders defined by the presence of autoantibodies in plasma and/or CSF have recently been discovered, most often first described in the context of paraneoplastic syndromes, only later to be also found unassociated with tumors. These include limbic encephalitis (e.g., anti-NMDAR, anti-AMPAR, anti- GABABR, anti-LGI1, anti-CASPR2), cerebellar ataxias (e.g., anti-Yo, anti-DNER, anti-GAD), stiff-person syndrome (anti-GAD, anti-amphiphysin, anti-GlyR) and others (anti-Hu). Although little is known regarding the pathophysiology of these disorders, some are believed to be more B-cell or T-cell mediated, hypotheses mostly suggested by observed therapeutic responses and the surface/intracellular nature of antigens. Involvement of KIR and HLA is unexplored in these disorders. Intriguingly, our preliminary data support a strong Genome-Wide Association Study (GWAS) significant association of anti-NMDAR encephalitis with activatory KIR2DS1, the strongest KIR association ever reported, suggesting KIR-NK cell axis to be a key regulator for these disorders. We propose to conduct a genetic survey of the HLA and KIR repertoires in these diseases. Our specific aims 1 and 2, we will do a detailed characterization of symptoms and collect serum and DNA on 2000 cases (~1000 cases already collected). Our specific aim 3 will leverage state of the art advances in KIR and HLA next- generation sequencing to perform high resolution genotyping in cases and controls, in addition, we will also perform genome-wide single nucleotide typing in all cases and controls which will guide our association analysis. In our specific aim 4, we will perform association analyses of the genome wide genotyping, compare frequencies of HLA and KIR alleles in cases and controls. In our specific aim 5, any disorder with KIR and/or HLA finding(s) we will conduct KIR-HLA interaction analyses focusing on KIR with known HLA ligands. This will involve comparing frequencies of interacting KIR-HLA ligand pairs in cases versus controls; further, we will correlate KIR/HLA findings with disease severity or symptom clusters. The study of these disorders will benefit neurology, neuroimmunology, cancer, and infectious disease work. The fact these disorders are occurring in the setting of heightened tumor immunity is notable and relevant to cancer immunotherapy, a growing area. These datasets will be made available through ImmPort, which will allow countless researchers to prioritize basic studies of B cells, T and NK cells in these disorders and associated tumors.

摘要